{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse%2FRecurrence&page=10", "query": { "condition": "Relapse/Recurrence", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 3147, "total_pages": 315, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse%2FRecurrence&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse%2FRecurrence&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T19:44:50.472Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003666", "title": "Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "6-hydroxymethylacylfulvene", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 36, "start_date": "1998-11", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2016-07-20", "last_synced_at": "2026-11-03T19:44:50.472Z", "location_count": 48, "location_summary": "Birmingham, Alabama • La Jolla, California • San Francisco, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003666" }, { "nct_id": "NCT01644695", "title": "Review of Complex Recurrent Hernia Repair", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Recurrent Hernia" ], "interventions": [ { "name": "Bony Anchoring Reinforcement System", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Institute For Advanced Reconstruction", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 85, "start_date": "2011-10", "completion_date": "2020-01", "has_results": true, "last_update_posted_date": "2012-10-15", "last_synced_at": "2026-11-03T19:44:50.472Z", "location_count": 1, "location_summary": "Shrewsbury, New Jersey", "locations": [ { "city": "Shrewsbury", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01644695" }, { "nct_id": "NCT01681537", "title": "Lenalidomide Plus Chemotherapy for AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 36, "start_date": "2012-09", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2016-03-17", "last_synced_at": "2026-11-03T19:44:50.472Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01681537" }, { "nct_id": "NCT00673569", "title": "Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "needle biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2006-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-08-09", "last_synced_at": "2026-11-03T19:44:50.472Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00673569" }, { "nct_id": "NCT00004239", "title": "506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Compound 506U78", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "1999-12", "completion_date": "2002-01", "has_results": false, "last_update_posted_date": "2016-07-04", "last_synced_at": "2026-11-03T19:44:50.472Z", "location_count": 3, "location_summary": "Chicago, Illinois • Iowa City, Iowa • Winston-Salem, North Carolina", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004239" }, { "nct_id": "NCT05330377", "title": "GM-CLAG in Relapsed/Refractory FLT3-mutated AML", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Gilteritinib 40 MG Oral Tablet", "type": "DRUG" }, { "name": "Cladribine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ayman H Qasrawi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2023-03", "completion_date": "2032-05-30", "has_results": false, "last_update_posted_date": "2023-04-25", "last_synced_at": "2026-11-03T19:44:50.472Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05330377" }, { "nct_id": "NCT05117242", "title": "Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer Metastatic" ], "interventions": [ { "name": "Acasunlimab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2021-10-27", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-11-03T19:44:50.472Z", "location_count": 6, "location_summary": "Santa Rosa, California • Fort Myers, Florida • St. Petersburg, Florida + 3 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05117242" }, { "nct_id": "NCT06865677", "title": "Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Platinum Resistant Epithelial Ovarian Carcinoma", "Recurrent Epithelial Endometrial Carcinoma", "Recurrent Epithelial Cervical Carcinoma" ], "interventions": [ { "name": "Sacituzumab Govitecan", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "Brain MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "CT scans", "type": "DIAGNOSTIC_TEST" }, { "name": "Tumor biopsy", "type": "PROCEDURE" }, { "name": "Loperamide", "type": "DRUG" }, { "name": "Octreotide", "type": "DRUG" }, { "name": "Diphenoxylate/Atropine", "type": "DRUG" }, { "name": "Antiemetics", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 2, "start_date": "2025-06-09", "completion_date": "2025-07-01", "has_results": true, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-11-03T19:44:50.472Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06865677" }, { "nct_id": "NCT06922539", "title": "Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Fenretinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SciTech Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2025-12-11", "completion_date": "2028-10-01", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-11-03T19:44:50.472Z", "location_count": 2, "location_summary": "Los Angeles, California • Detroit, Michigan", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06922539" }, { "nct_id": "NCT00206388", "title": "Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "NEUROBLASTOMA" ], "interventions": [ { "name": "Zolendric acid", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 21, "start_date": "2005-04", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2013-08-02", "last_synced_at": "2026-11-03T19:44:50.472Z", "location_count": 8, "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00206388" } ] }